Ticker
$IMNM
1 catalyst touching IMNM in the last 60 days, newest first, each with the price move that followed.
- 72
Immunome eliminates BMS royalty obligations, acquires patent rights for $20M cash plus shares
Immunome paid Bristol-Myers Squibb $20 million in cash and issued 4.4 million shares to eliminate all milestone and royalty payment obligations under a license agreement dating to 2017, and to acquire full patent rights to varegacestat and AL101. This removes future cash drain from the Company's pipeline assets and converts contingent liabilities into equity, which may be viewed positively by growth-stage biotech investors, though the ~4.4M share issuance represents dilution that depends on current share count context.
IMNM ▲SEC 8-K · 5 Oct 2026, 12:30 UTC
Information only. AURA does not give buy or sell recommendations.